|
시장보고서
상품코드
1983212
호흡기 의약품 시장 : 약물 종류별, 용도별, 유통 채널별, 지역별Pulmonary Drugs Market, By Drug Class, By Application, By Distribution Channel, By Geography |
||||||
호흡기 의약품 시장은 2026년에 566억 달러로 추정되며, 2033년까지 965억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.1%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 566억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 8.10% | 예측 금액(2033년) | 965억 달러 |
호흡기 의약품은 폐에 영향을 미치는 질환을 치료하는 데 사용됩니다. 호흡기 의약품은 감기와 같은 가벼운 질환부터 천식과 같은 장기적인 질환의 치료까지 폭넓게 사용되고 있습니다. 이 약제들은 경구 정제, 경구용 액상, 주사제, 흡입제 등 다양한 제형으로 제공되고 있습니다. 흡입제는 약물을 폐에 직접 전달하기 때문에 폐 조직에 직접 작용하여 전신 부작용을 최소화할 수 있습니다.
시장 역학
호흡기 의약품 시장의 성장을 이끄는 주요 요인으로는 만성 호흡기질환의 유병률 증가, 흡연, 정부 및 비정부 차원의 노력 등이 있습니다. 미국 질병예방통제센터(CDC)에 따르면, 2015년 미국에서는 2,500만 명이 천식을 앓고 있으며, 이는 미국인 13명 중 1명이 천식을 앓고 있다는 것을 의미합니다. 18세 미만에서는 620만 명이 천식을 앓고 있었습니다. 연간 천식으로 인한 의사 진료는 1,420만 건, 응급실 방문은 1,800만 건에 달합니다. 또한, 브랜드 의약품의 잇따른 특허 만료, 연구개발에 대한 자금 투입, 혁신적인 제품 출시가 예측 기간 동안 시장 성장의 주요 요인으로 작용할 것으로 예상됩니다. 예를 들어, 2017년 GSK는 만성 폐질환을 위한 3제 복합 흡입기 '트레레지 엘립타(Trelegy Ellipta)'에 대해 미국 식품의약국(FDA)의 승인을 획득한 바 있습니다. 트레레지 엘리프타는 세 가지 치료법을 하나의 흡입기에 통합하여 환자들에게 새로운 치료 옵션을 제공합니다. 그러나 진단을 받지 않은 환자가 다수 존재하고, 이들 약물의 사용에 따른 부작용(신장 손상을 유발하고 유해한 결과를 초래할 수 있음)이 시장 성장을 제한할 것으로 예상됩니다.
본 보고서의 주요 특징
- 세계의 호흡기 의약품 시장을 상세히 분석하고, 2025년을 기준 연도로 하여 예측 기간(2026-2033년)의 시장 규모와 CAGR을 조사하여 전해드립니다.
- 또한, 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 호흡기 의약품 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 정리하여 수록하고 있습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 호흡기 의약품 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 호흡기 의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 호흡기 의약품 시장 : 약물 종류별(2026-2033년)
제5장 세계의 호흡기 의약품 시장 : 용도별(2026-2033년)
제6장 세계의 호흡기 의약품 시장 : 유통 채널별(2026-2033년)
제7장 세계의 호흡기 의약품 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSM 26.04.20Pulmonary Drugs Market is estimated to be valued at USD 56.6 Bn in 2026 and is expected to reach USD 96.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 56.6 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.10% | 2033 Value Projection: | USD 96.5 Bn |
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
Market Dynamics
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.
Key features of the study
- This report provides in-depth analysis of pulmonary drugs market and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 - 2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global pulmonary drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
- Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
- Inhaled Corticosteroids
- Long Acting Beta-2 Agonists
- Antihistamines
- Vasodilators
- Short Acting Beta-2 Agonists
- Others
- Application Insights (Revenue, USD Bn, 2026 - 2033)
- Asthma & COPD
- Allergic Rhinitis
- Pulmonary Arterial Hypertension
- Cystic Fibrosis
- Others
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Sanofi SA
- Meda Pharmaceuticals
- Circassia Pharmaceuticals Plc.
- AstraZenca Plc.
- GlaxoSmithKline Plc.
- Mallinckrodt Pharmaceuticals Plc.
- Cheisi farmaceutici S.p.A.
- Zambon Company S.p.A.
- Alaxia SAS
- Merck Sharp & Dohme Limited
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Regulatory Scenario
- Pipeline Analysis
- Promotional Activities and Campaigns
- Supply Chain Analysis
- PEST Analysis
- Epidemiology
4. Global Pulmonary Drugs Market, By Drug Class, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Inhaled Corticosteroids
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Long Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Antihistamines
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Vasodilators
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Short Acting Beta-2 Agonists
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
5. Global Pulmonary Drugs Market, By Application, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Asthma & COPD
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Allergic Rhinitis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pulmonary Arterial Hypertension
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Cystic Fibrosis
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
6. Global Pulmonary Drugs Market, By Distribution Channel, 2026 - 2033, (USD Bn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- E-Commerce
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
7. Global Pulmonary Drugs Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
- North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Sanofi SA
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Meda Pharmaceuticals
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Circassia Pharmaceuticals Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- AstraZeneca Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- GlaxoSmithKline Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Mallinckrodt Pharmaceuticals Plc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Cheisi Farmaceutici S.p.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Zambon Company S.p.A
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Alaxia SAS
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Merck Sharp & Dohme Limited
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Analyst Views
- Sanofi SA
9. Section
- References
- Research Methodology
- About Us and Sales Contact
